The National Cancer Institute approved a $10 million award for OHSU Cancer Institute
On Jul. 18, 2005, Oregon Health & Science University (OHSU) announced receipt of a five-year, $10 million award…
On Jul. 18, 2005, Oregon Health & Science University (OHSU) announced receipt of a five-year, $10 million award…
On Jun. 29, 2005, the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005 (P.L. 109-18) amended…
On May 1, 2005, The Wayne State University Karmanos Cancer Institute announced it had acquired its clinical facilities…
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
On Apr. 8, 2005, Moores Cancer Center (MCC) at University of California, San Diego opened its new consolidated…
On Mar. 16, 2005, University of California, Los Angeles (UCLA) officials announced the formation of the Institute for…
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
In 2005, The Patient Navigator Research Program (PNRP), a National Cancer Institute initiative, was underway to assess the…
In 2005, the Georgia Legislature passed the Smoke Free Air Act, banning indoor smoking in publicly accessible buildings,…
On Dec. 10, 2004, a National Cancer Institute (NCI) supported study determined that a new molecular test done…
On Nov. 18, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Genentech’s drug Tarceva…
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
Apr. 14, 2004, the National Center for Vermiculite and Asbestos-Related Cancers was established in Michigan in response to…
On Mar. 16, 2004, the Food and Drug Administration (FDA) released a report addressing the recent slowdown in…
On Feb. 26, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved the first antiangiogenic…
On Feb. 1, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Cetuximab, a recombinant…
On Jan. 9, 2004, the Food and Drug Administration (FDA) announced the approval of Sanofi’s Eloxatin (oxaliplatin) injection…
In 2004, the National Cancer Institute (NCI) collaborated with the Department of Health and Human Services to establish…
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
On Jan. 20, 2005, the Siteman Cancer Center received National Cancer Institute (NCI) designation as a Comprehensive Cancer…
In 2004, the Oklahoma Medical Research Foundation (OMRF) opened the state’s first small animal magnetic resonance imaging facility….
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…
On Jun. 21, 2004, the Huntsman Cancer Center Hospital was dedicated featuring a full-field digital mammography unit, a…
On Nov. 19, 2003, a novel approach to treatment of solid cancers involved therapeutic agents that inhibit the…
On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who…
On Sept. 3, 2003, the death rates from the four most common cancers, – lung, breast, prostate, and…
On Jun. 24, 2003, results of the Prostate Cancer Prevention Trial (PCPT), testing the effectiveness of finasteride to…
On Jun. 5, 2003, data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial gave fresh insight…
On May 30, 2003, the Attorney General of California consented to the sale of the assets of the…